Steve is responsible for all aspects of clinical development. Prior roles were in R&D at Bristol Myers Squibb (BMS) for 6 years, Pfizer for 9 years, and Kyowa Kirin for 7 years. During his career at BMS and Pfizer, Steve chaired several Development Teams in Oncology leading the early development of several novel agents for the treatment of cancer including dasatinib, antivasculars, CDK inhibitors, chemotherapeutics, and signal transduction inhibitors. At Pfizer, as VP of Clinical Development, Steve was a Global Clinical Leader for several clinical programs in oncology and was also Head of Translational Medicine for Pfizer Oncology and Development Team Leader for the entire Signal Transduction portfolio including EGFR, HER2, panHER, cMET, ALK, FAK, MEK, AKT, and the PI3K/MTOR projects. At Kyowa Kirin, Steve had global responsibility for oncology development and was also responsible for development of KHK’s innovative portfolio in immunology, nephrology, neurology and rare disease in the US and EU. Key achievements while at KHK include driving 3 first in class NMEs from early development through phase 3 and to approval in 5 years (mogamulizumab, burosumab, and istradefylline).

Steve received his B.S., Pharm.D., and Ph.D. degrees at Duquesne University, the Philadelphia College of Pharmacy and Science, and the University of North Carolina at Chapel Hill. Steve completed a fellowship at University of North Carolina and Burroughs Wellcome and is an author and contributor on many peer-reviewed manuscripts.